Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2001; 21(1): 009-014
DOI: 10.1055/s-2001-13114
DOI: 10.1055/s-2001-13114
Dopamine Agonists
Further Information
Publication History
Publication Date:
31 December 2001 (online)
ABSTRACT
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ropinirole) and apomorphine, another agonist presently under investigation, are discussed.
KEYWORD
Dopamine agonists - Parkinson's disease - Parkinson's disease treatment
REFERENCES
- 1 Tanaka M, Sotomatsu A, Kanai H. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci . 1991; 101 198-203
- 2 Walkinshaw G, Waters C M. Induction of apoptosis in catecholaminergic PC 12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest . 1995; 95 2458-2464
- 3 Agid Y. Levodopa: is toxicity a myth?. Neurology . 1998; 50 858-863
- 4 Watts R L. The role of dopamine agonists in early Parkinson's disease. Neurology . 1997; S34-S48 (S34-S48)
- 5 Pearce R KB, Banerji T, Jenner P. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naive MPTP-treated common marmosets. Br J Pharmacol . 1996; 118 37
- 6 Bedard P J, Gomez-Mancilla B, Blanchet P. Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA, eds. Dopamine Agonists in Early Parkinson's Disease
Kent, UK: Wells Medical 1997: 101-113
MissingFormLabel
- 7 Chase T N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs . 1998; 55 S1-S9
- 8 Chase T N, Engber T M, Mouradian M M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology . 1994; 44 S15-S18
- 9 Lees A J, Stern G M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry . 1981; 44 1020-1023
- 10 Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C. A six month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol . 1998; 21 358-362
- 11 Adler C H, Sethi K D, Hauser R A. Ropinirole for the treatment of early Parkinson's disease. Neurology . 1997; 49 393-399
- 12 Kreider M, Knox S, Gardiner D. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease. Neurology . 1996; 46 A475
- 13 Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA . 1997; 278 125-130
- 14 Shannon K M. New alternatives for the management of early Parkinson's disease (PD). Mov Disord . 1996; 11 S266
- 15 Carrion A, Weiner W J, Shulman L M. A three and a half-year experience with pramipexole monotherapy in patients with early Parkinson's disease. Neurology . 1998; 50 A330
- 16 Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist?. Neurology . 1998; 51 S21-S24
- 17 Olanow C W, Fahn S, Muenter M. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord . 1994; 9 40-47
- 18 Assal F, Spahr L, Hadengue A. Tolcapone and fulminant hepatitis. Lancet . 1998; 352 958
- 19 Stern M B. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology . 1997; S2-S9 (S2-S9)
- 20 Corrodi M, Fuxe K, Hokfelt T. Effect of ergot drugs on central catecholaminergic neurons: evidence for stimulation of central dopamine neurons. J Pharm Pharmacol . 1973; 25 409-412
- 21 Calne D B, Teychenne P F, Claveria L E. Bromocriptine in parkinsonism. BMJ . 1974; 4 442-444
- 22 Kartsinel R, Teychenne P, Gillespie M M. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet . 1976; 2 272-275
- 23 Lieberman A, Kupersmith M, Estey E. Treatment of Parkinson's disease with bromocriptine. N Engl J Med . 1976; 295 1400-1404
- 24 Pezzoli G, Martignoni E, Pacchetti, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology. 1995; S22-S27
- 25 Goetz C G, Tanner C M, Glantz R H. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985; 35 749-751
- 26 Lieberman A N, Neophytides A, Leibowitz M. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol . 1983; 37 95-108
- 27 Shannon K M, Bennett Jr P J, Friedman J H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology . 1997; 49 724-728
- 28 Hubble J P, Koller W C, Cutler N R. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol . 1995; 18 338-347
- 29 Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology . 1997; 49 1060-1065
- 30 Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology . 1997; 49 162-168
- 31 Molho E S, Factor S A, Weiner W J. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm . 1995; 45 S225-S230
- 32 Sethi K D, O'Brien C F, Hammerstad J P. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol . 1998; 55 1211-1216
- 33 Brooks D J, Abbott R J, Lees A J. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol . 1998; 21 101-107
- 34 Korczyn A D, Brooks D J, Brunt E R. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord . 1998; 13 46-51
- 35 Rascol O, Brooks D J, Brunt E R. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord . 1998; 13 39-45
- 36 Brooks D J, Tornjanski N, Burn D J. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm . 1995; 45 S231-S238
- 37 Rascol O, Lees A J, Senard J M. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol . 1996; 19 234-245
- 38 Pryse-Phillips W. Companion to Clinical Neurology.
Boston: Little, Brown 1995: 303-304
MissingFormLabel
- 39 Rinne U. Pleuropulmonary changes during long term bromocriptine treatment for Parkinson's disease. Lancet . 1981; 3 44-45
- 40 Shaunak S, Wilkins A, Pilling J B. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry . 1999; 66 79-81
- 41 Rajput A H. Adverse effects of ergot-derivative dopamine agonists. In: Olanow CW, Obeso JA, eds. Dopamine Agonists in Early Parkinson's Disease
Kent, UK: Wells Medical 1997: 209-216
MissingFormLabel
- 42 Sibley D R, Monsma Jr J F. Molecular biology of dopamine receptors. Trends Pharmacol Sci . 1992; 13 61-69
- 43 Robertson H A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci . 1992; 15 201-205
- 44 Piercey M F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol . 1998; 21 141-151
- 45 Frucht S, Rogers J D, Greene P E. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology . 1999; 52 1908-1910
- 46 Weill E. De l'apomorphine dans certains troubles nerveux. Lyon Med . 1884; 48 411-419
- 47 Schwab R S, Mador L V, Levine J Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc . 1951; 76 273-279
- 48 Cotzias G C, Papavasiliou P S, Tolosa E S. Treatment of Parkinson disease with apomorphines: possible role of growth hormone. N Engl J Med . 1976; 294 567-572
- 49 Ondo W G, Hunter C, Almaguer M. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord . 1999; 14 664-668
- 50 Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology . 1998; 51 S13-S20
- 51 Piccoli F, Riuggeri R M. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm . 1995; 45 S187-S195